Pacira Pharmaceuticals (NASDAQ:PCRX) is set to issue its quarterly earnings data before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of $0.11 per share for the quarter.
Shares of Pacira Pharmaceuticals (PCRX) opened at $30.15 on Tuesday. The company has a market capitalization of $1,220.00, a price-to-earnings ratio of -23.02 and a beta of 1.88. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a 1 year low of $29.35 and a 1 year high of $58.95.
In related news, CEO David M. Stack sold 28,885 shares of the stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.60% of the company’s stock.
PCRX has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, October 25th. Janney Montgomery Scott cut Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 price objective for the company. in a research report on Thursday, October 26th. Piper Jaffray Companies reiterated a “buy” rating and set a $55.00 price objective on shares of Pacira Pharmaceuticals in a research report on Friday, October 27th. Canaccord Genuity cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $44.00 to $33.00 in a research report on Monday, October 30th. Finally, BMO Capital Markets upped their price target on Pacira Pharmaceuticals from $38.00 to $39.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 8th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $46.53.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.